We are live on ! Find out more
CGEM icon

Cullinan Therapeutics

96 hedge funds and large institutions have $396M invested in Cullinan Therapeutics in 2022 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 42 increasing their positions, 22 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

333% more call options, than puts

Call options by funds: $13K | Put options by funds: $3K

91% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 22

47% more capital inflows, than outflows

Capital inflows: $19M | Capital outflows: $13M

0.85% more ownership

Funds ownership: 81.18% → 82.03% (+0.85%)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

8% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 13

3% less funds holding

Funds holding: 99 → 96 (-3)

Holders
96
Holders Change
-3
Holders Change %
-3.03%
% of All Funds
1.54%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
12
Increased
42
Reduced
22
Closed
13
Calls
$13K
Puts
$3K
Net Calls
+$10K
Net Calls Change
-$492K

CGEM Hedge Fund Activity: Q4 2022 in Review

96 of the 6,245 institutional investors tracked by Wall St. Rank reported a position in Cullinan Therapeutics (CGEM) for Q4 2022, worth a combined $396M — down 17% from $475M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of CGEM and 12 opened new positions — a net loss of 1 holder — while 22 trimmed existing stakes and 42 added.

The largest buyer was Woodline Partners, opening a new position worth an estimated $2.38M. The largest seller was Baupost Group, exiting entirely with an estimated $5.51M sold.

  • 96 institutional investors held Cullinan Therapeutics (CGEM) as of Q4 2022, down from 99 in Q3 2022.
  • Funds reported $396M of Cullinan Therapeutics stock for Q4 2022, down 17% quarter-over-quarter.
  • 12 funds opened new Cullinan Therapeutics positions in Q4 2022 and 13 closed out, a net change of -1 holder.
  • The largest Cullinan Therapeutics buyer in Q4 2022 was Woodline Partners, an estimated $2.38M added.
  • The largest Cullinan Therapeutics seller in Q4 2022 was Baupost Group, an estimated $5.51M sold.

Based on aggregated 13F filings for Q4 2022.